PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: Jones Public Affairs, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Prostate Mapping Biopsy Impacting Treatment Decisions Says A Recent Study - Latest Technique for Prostate Cancer Diagnosis decreases need for Prostatectomy - ProstateConditions.org / JonesPA.com
Prostate Mapping Biopsy Impacting Treatment Decisions Says A Recent Study

 

NewswireToday - /newswire/ - Washington, DC, United States, 2011/07/18 - Latest Technique for Prostate Cancer Diagnosis decreases need for Prostatectomy - ProstateConditions.org / JonesPA.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The diagnosis and treatment of prostate cancer (PCa) is currently undergoing a revolution similar to that seen over the past three decades with respect to the improvements made in breast cancer screening, diagnosis and treatment options. The long-standing gold standard for PCa diagnosis is the Transrectal Ultrasound (TRUS) guided prostate needle biopsy. While TRUS is still used to make an initial diagnosis, in recent years, the development of a staging prostate biopsy – the Transperineal 3D Mapping Biopsy – has been introduced, allowing physicians to better understand the stage and gravity of the cancer in order to make more informed treatment decisions.

“We have been working hard to bring prostate cancer diagnosis and treatment to more advanced states. Our approach follows similar efforts from breast cancer patients and advocates, which have led to the decline of radical mastectomies, an increase in research and better diagnostic test, treatment and surgical options,” said Dr. E. David Crawford, Chairman, Prostate Conditions Education Council and Professor of Urology and Radiation Oncology, University of Colorado.

Experts agree that prostate staging biopsies will yield better understanding of the extent and aggressiveness of the disease in patients. This information allows physicians to develop individualized treatment plans for patients. “We expect to see a decline in the number of men who are undergoing unnecessary prostatectomies or radiotherapy,” said Dr. Crawford. “This, coupled with new focalized treatments that are the equivalent of the ‘male lumpectomy’ should help us see an increase in positive outcomes for men diagnosed with the disease.”

Prostate Mapping Biopsy vs. TRUS
The TRUS needle biopsy is an outpatient surgical procedure in which a transrectal ultrasound is used to create an image of the prostate, allowing a physician to guide a small needle to take 6-12 samples of prostate tissue to test for abnormal cells and tissue. For many years, it has been the definitive way to diagnose prostate cancer. But under- and over- grading of the cancer is common.[1] This can lead to patients undergoing treatments that are unnecessarily invasive or being subjected to the risk of associated morbidities from other treatment methods.

The Prostate Staging Biopsies (PSB) Procedure is performed as an outpatient procedure under general anesthesia. It allows physicians to create a three-dimensional image of the prostate, including the location of the cancer within the organ. As PSB can better determine the size and location of the cancer, it allows patients and their physicians to more appropriately select a treatment option, including ongoing evaluation.

In a recent study, 215 men underwent PSB. Of those, only 38 chose to have radical prostatectomy, while the majority of the remaining men underwent targeted therapy and 44 elected to watch and wait.[2]

No studies have reported a significant difference in the risks or complications between the two procedures.

“The Prostate Cancer Staging procedure helped me to better understand the extent of my prostate cancer and to make a treatment decision based on more complete information than I otherwise would have had,” said patient Larry Biro. “For me and my family, it was an invaluable tool that addressed many of the normally unanswered questions that men in my position have.”

Prostate Cancer is the Second Leading Cause of Cancer Deaths in American Men; Enormous Economic Impact for Patients

Prostate cancer is the number two cause of cancer deaths in American men.[3] According to the National Cancer Institute, there were an estimated 217,730 new diagnoses and 32,050 deaths from prostate cancer in the United States in 2010.[4] One in six men over age 40 will develop prostate cancer.[5] It is typically diagnosed in men over the age 65, and African-American men are in the highest risk group.

According to the National Institutes of Health, the U.S. expenditure for prostate cancer care was expected to be $12 billion, making it the fifth most costly type of cancer behind breast ($16.5B), colorectal ($14.14B), lymphoma ($12.14B) and lung ($12.12B) cancers.[6]

About Prostate Conditions Education Council (PCEC)
A national organization committed to men’s health, the Prostate Conditions Education Council (prostateconditions.org) – formally the Prostate Cancer Education Council – is the nation’s leading resource for information on prostate health. The PCEC is dedicated to saving lives through awareness and the education of men, the women in their lives, as well as the medical community about prostate cancer prevalence, the importance of early detection, and available treatment options, as well as other men’s health issues. The Council – comprised of a consortium of leading physicians, health educators, scientists and prostate cancer advocates – aims to conduct nationwide screenings for men and perform research that will aid in the detection and treatment of prostate conditions.

REFERENCES:
[1] Al B. Barqawi MD, Kyle O. Rove MD, Saeed Gholizadeh, Colin I. OʼDonnell MS, Hari Koul PhD, E. David Crawford MD, The Role of 3-Dimensional Mapping Biopsy in Decision Making for Treatment of Apparent Early-Stage Prostate Cancer, page 3.
[2]Al B. Barqawi MD, Kyle O. Rove MD, Saeed Gholizadeh, Colin I. OʼDonnell MS, Hari Koul PhD, E. David Crawford MD, The Role of 3-Dimensional Mapping Biopsy in Decision Making for Treatment of Apparent Early-Stage Prostate Cancer, page 7.
[3]Kyle O. Rove, MD, Kathryn F. Sullivan, MD, E. David Crawford, M, High-intensity Focused Ultrasound: Ready for Primetime, page 1
[4]National Cancer Institute Prostate Cancer Web Page.
[5]PCEC website
[6]National Institutes of Health, National Expenditures and Cost of Cancer Care for 2010

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Jones Public Affairs, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Prostate Mapping Biopsy Impacting Treatment Decisions Says A Recent Study

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Deborah Danuser - JonesPA.com 
202-591-4043 tara[.]jonespa.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Jones Public Affairs, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Jones Public Affairs, Inc. / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Sustainable Alternatives to Polyvinylidene Chloride-coated Films Create Growth Opportunities & Transform the Food Packaging Markets in Western Europe
RIKEN Biofunctional Synthetic Chemistry Laboratory in Japan Has Developed A Way to Engineer Glycan Complexes Clusters of Sugar Chains
The Clinicians of Longs Peak Emergency Physicians Join US Acute Care Solutions
Frost & Sullivan Recognizes BroadReach for Improving the Health and Wellbeing of Underserved Populations
Silver Spring Emergency Physicians Join US Acute Care Solutions
Stress Light Therapy Launches Crowd-Funded Campaign on Indiegogo.com
The Float Space - Brisbane's First Float and Cryo Therapy Centre to Open This November
Thought Leaders Across the Healthcare Spectrum to Participate in Industry-Wide Survey
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Moriarty Physical Therapy of the Hudson Valley Expands with New Office in Lagrange, NY
Ultimate Medical Group Announces A New Regenerative Medicine Division
Dr. Amir Hanna Introduces New Medical Innovation Taking the Pain Out of Physical Therapy
Samitivej Children’s Hospital Transforms its Sukhumvit Campus

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)